News Releases
Nov 08, 2024 Xeris Biopharma Reports Third Quarter 2024 Financial Results Achieved record total revenue of $54.3M including record product revenue of $52.9M Product revenue increased 27% versus prior year and 14% over the prior quarter Ended Q3 with $69.4M in cash, cash equivalents and short-term investments Raises full-year guidance of total net revenue to $198M-$202M
Oct 31, 2024 Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024 Conference call and webcast at 8:30am ET CHICAGO --(BUSINESS WIRE)--Oct. 31, 2024-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies,
Oct 04, 2024 Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) CHICAGO --(BUSINESS WIRE)--Oct. 4, 2024-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2024 , the
Aug 22, 2024 Xeris to Participate in Upcoming Investor Conferences CHICAGO --(BUSINESS WIRE)--Aug. 22, 2024-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior
Aug 08, 2024 Xeris Biopharma Reports Second Quarter 2024 Financial Results Achieved revenue of $48.1M including record product revenue of $46.5M Total revenues increased 18% over the prior quarter and 26% over the same period prior year Ended Q2 with $77.6M in cash, cash equivalents and short-term investments Tightens full-year 2024 guidance: total net revenue to
Jul 25, 2024 Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024 Conference call and webcast at 8:30am ET CHICAGO --(BUSINESS WIRE)--Jul. 25, 2024-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies,
Jul 08, 2024 Xeris Biopharma Announces CEO Succession Plan John Shannon , President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track record of its
Jul 03, 2024 Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) CHICAGO --(BUSINESS WIRE)--Jul. 3, 2024-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024 , the
Jun 03, 2024 Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024 In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower mUFC at baseline was also associated with lower maintenance dose requirements and lower rates of potentially clinically important liver-related adverse
May 30, 2024 Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) XeriSol™ formulation enabled predictable bioavailability and sustained levels of levothyroxine in a once-weekly subcutaneous presentation Once-weekly SC levothyroxine (XP-8121) participants normalized TSH/T4 levels using 45% less drug than would be needed for their daily oral dose on a weekly basis
Request email alerts
IMAGES